文章摘要
智会静,詹骁靖,李浩,左晓春,邵颖,吕心欢,周凌芸.新药临床试验期间药物警戒和风险控制研究二:临床试验方案、研究者手册和知情同意书监管要求研究[J].中国药事,2022,36(6):624-629
新药临床试验期间药物警戒和风险控制研究二:临床试验方案、研究者手册和知情同意书监管要求研究
Research II on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: A Study on Regulatory Requirements of Pharmacovigilance for Clinical Trial Protocols, Investigator's Brochure and Informed Consent Forms
  
DOI：10.16153/j.1002-7777.2022.06.004
中文关键词: 药物警戒  临床试验方案  研究者手册  知情同意书  药品监管
英文关键词: pharmacovigilance  clinical trial protocols  investigator's brochure  informed consent forms  drug regulation
基金项目:
作者单位
智会静 长春金赛药业有限责任公司,北京 100045 
詹骁靖 江苏恒瑞医药股份有限公司,上海 201203 
李浩 康龙化成(成都)临床研究服务有限公司,成都 610041 
左晓春 沈阳药科大学亦弘商学院,北京 100055 
邵颖 沈阳药科大学亦弘商学院,北京 100055 
吕心欢 沈阳药科大学亦弘商学院,北京 100055 
周凌芸 赛诺菲(中国)投资有限公司上海分公司,上海 200040 
摘要点击次数: 983
全文下载次数: 347
中文摘要:
      目的：对比临床试验期间国内外临床试验方案、研究者手册、知情同意书这三个关键要素中关于药物警戒监管的差异，为我国科学监管提出建议，从而加强新药临床试验期间安全性风险控制及受试者保护。方法：通过文献和法规研究，对比临床试验期间国内外临床试验方案、研究者手册、知情同意书这三个关键要素中关于药物警戒监管的差异，就如何更好应用临床试验方案、研究者手册、知情同意书保护受试者展开讨论。结果与结论：临床试验方案、研究者手册、知情同意书是临床研究中关于风险控制和受试者保护的关键安全性管理要素。我国临床试验期间上述三项管理要求的指导原则尚待完善，目前规定大多仅基于ICH的普遍要求，缺少基于国内行业现状的监管及指导。
英文摘要:
      Objective: To put forward suggestions for China's scientifi c supervision in order to strengthen the risk control on safety and protection on subjects during clinical trials of new drugs after comparing the diff erences of pharmacovigilance supervision at home and abroad about the three key elements of clinical trial protocols, investigator's brochure, and informed consent forms during clinical trials. Methods: Through literature search and reviews of regulations, the diff erences in domestic and foreign regulations on pharmacovigilance about thehree key elements of clinical trial protocols, investigator's brochure and informed consent forms were compared. Discussions were conducted on how to better apply clinical trial protocols, investigator's brochure and informed consent forms to protect subjects. Results and Conclusion: The clinical trial protocols, investigator's brochure, and informed consent forms are the key safety management elements for risk control and protection on subjects in clinical trials. The guidelines for the above three management requirements during clinical trials in China need to be further improved. Most of the current regulations are formed only to meet the general requirements of ICH and there is a lack of supervisions and guidances consistent with the current situation of the domestic industries.
查看全文   查看/发表评论  下载PDF阅读器
关闭